Previous 10 | Next 10 |
Halozyme Therapeutics, Inc. (HALO) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen Torley - President & Chief Executive Officer Nicole LaBrosse...
Halozyme ( NASDAQ: HALO ) stock gained 8.5% to $47.00 in Tuesday postmarket trading, after the company reported a rise in Q2 revenue, helped in part by a recent acquisition, and raised its FY 2022 guidance. San Diego, Calif.-based HALO develops drug delivery systems. Its...
Halozyme Therapeutics press release ( NASDAQ: HALO ): Q2 Non-GAAP EPS of $0.53. Revenue of $152.37M. Financial Outlook for 2022 The Company is raising its financial guidance for 2022 which was last provided on May 10, 2022, as a result of the recent close of the An...
HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS PR Newswire Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022 Second Quarter Revenue Increased 12...
Today, we take a look at Halozyme Therapeutics for the first time in many years. The company has a fairly unique business model within the healthcare space and is delivering consistent growth. An investment analysis follows in the paragraphs below. Evil is a choice o...
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer PR Newswire Subcutaneous formulation with ENHANZE ® reduced treatment time to 3-8 minutes...
We once again made Avid Bioservices a large position during the quarter. Unlike most biotech stocks, Avid is a real business, not a binary bet on whether or not a drug will meet its hoped-for end state. At the prices we were buying CDMO, the stock was perhaps 3 or 4 years away fro...
For Q2 2022 Class A interests in Laughing Water Capital returned approximately -19.4%, bringing our year to date returns to approximately -29.5%. We are consciously choosing to accept greater volatility in exchange for the potential to realize greater long-term returns. I believe ...
Halozyme to Report Second Quarter 2022 Financial and Operating Results PR Newswire SAN DIEGO , July 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2022 financial and oper...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have suffered significant setbacks during the first half of the year. Investors had little appetite for innovation-driven companies, seeking safe haven in more traditional stocks delivering steady profits...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...